Prelude Therapeutics 

Yahoo Finance • last month

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT1... Full story

Yahoo Finance • 4 months ago

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways... Full story

Yahoo Finance • 5 months ago

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2... Full story

Yahoo Finance • 5 months ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the C... Full story

Yahoo Finance • 5 months ago

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment... Full story

Yahoo Finance • 6 months ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026... Full story

Yahoo Finance • 6 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclin... Full story

Yahoo Finance • 6 months ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective tod... Full story

Yahoo Finance • 11 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare con... Full story

Yahoo Finance • last year

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer... Full story

Yahoo Finance • last year

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual G... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Incorporated (NASDAQ: PRLD) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

Insiders who bought US$263.0k worth of Prelude Therapeutics Incorporated (NASDAQ:PRLD) stock in the last year have seen some of their losses recouped as the stock gained 25% last week. The purchase, however, has proven to be a pricey bet,... Full story

Yahoo Finance • 2 years ago

Investor Alert: Abbott Cooper PLLC Investigates Prelude Therapeutics Incorporated; Urges Prelude Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude” or the “Company”) on behalf of the Company’s investors. The objective of this investigati... Full story

Yahoo Finance • 2 years ago

Q3 2023 Abcellera Biologics Inc Earnings Call

Participants Andrew Booth; CFO; AbCellera Biologics Inc. Carl L.G. Hansen; CEO, President & Chairperson; AbCellera Biologics Inc. Tryn T. Stimart; Chief Legal Officer, Chief Compliance Officer & Corporate Secretary; AbCellera Biologics... Full story

Yahoo Finance • 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program b... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

WILMINGTON, Del. & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discov... Full story

Yahoo Finance • 3 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm

PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s common s... Full story

Yahoo Finance • 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare inve... Full story